Recombinant antibody structures binding to and blocking the activity of vascular endothelial growth factor 2 (VEGFR—2/KDR)
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Nov 24, 2015
Grant Date -
Jul 17, 2014
app pub date -
Jul 7, 2010
filing date -
Jul 7, 2010
priority date (Note) -
In Force
status (Latency Note)
Importance
Abstract
Phage displayed recombinant antibody library was developed and the library was screened against VEGFR-2. After screening and ELISA experiments two recombinant antibodies showing binding properties to VEGFR-2 was obtained. The difference of the two recombinant antibodies to the recombinant antibodies already developed was demonstrated by DNA sequence analysis. The inhibition effect of the two recombinant antibodies on endothelial cell proliferation was demonstrated with cell assays. Thus these recombinant antibodies might be used as VEGF related angiogenesis inhibitors.
First Claim
Family
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully